Fig. 1

CA140 reduces Aβ/tau aggregate formation, Aβ levels, and AD pathology in vitro and in vivo. A Graph of fluorescence intensity versus concentration of CA140 in the presence of aggregated Aβ42 (average fluorescence measurements from three independent experiments). B Real-time monitoring of the inhibitory effects of CA140 on amyloid formation. C Quantification of the ThT intensity of Aβ42 at the final time point. D, E Aβ levels in primary cortical neurons and APP-overexpressing CHO cells. F–I Eight-month-old 5xFAD mice were injected with vehicle (10% DMSO) or CA140 (30 mg/kg) daily for 14 days, and immunofluorescence (IF) staining of brain slices was conducted with an anti-Aβ_17-24 (4G8) antibody (n = 16 brain slices from 4 mice/group). J, K Quantification of the ThT intensity of 2N4R full-length tau at the final time point. L, M 8-month-old 5xFAD mice were injected with vehicle (10% DMSO) or CA140 (30 mg/kg, i.p.) daily for 14 days, and IF staining of brain slices was conducted with an anti-Tau^{Thr212/Ser214} (AT100) antibody (Veh, n = 18 brain slices from 4 mice; CA140, n = 20 brain slices from 4 mice). Scale bar = 200 μm. *p < 0.05, **p < 0.01